FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1518669466> ?p ?o ?g. }

• W1518669466 abstract "Hepatitis A virus (HAV) infection is one of the most common cusses of acute viral hepatitis as well as a major health problem in the worldwide especially in the developing countries. Annually, 1.5 million of symptomatic cases of hepatitis A are estimated worldwide, but HAV seroprevalence data indicate that 10 million infections occur each year.[1] HAV is an acute, self-limiting infection of the liver that usually spread through oral-fecal rout.[2] Studies in various communities have shown that HAV prevalence rises with age and the risk of fulminant hepatitis associated with HAV infection is more in adolescence.[3] The prevalence of virus differs significantly in different parts of the world according to the geographic area, prevailing hygiene, sanitary conditions and socioeconomic levels and other development indicators.[4] In high endemic area, majority of people are infected with HAV in childhood while disease usually occurs asymptomatic, this explains why clinical hepatitis A is uncommon. On the other hand, in low or non-endemic area where people do not have natural immunity against HAV, they are susceptible to be infected with HAV that can be more symptomatic even fatal[5] and in rare cases may need to liver transplantation.[6,7]In Iran, we do not have surveillance system for reporting acute HAV infection yet but the seroprevalence of HAV infection in cross sectional studies was determined to be different across regions of Iran and different population based study. First time in 1980, Farzadegan et al. reported an almost complete immunity against HAV among adults after 30 years old.[8] Tow decades later, in 2004 among children less than 15 years old who visited in pediatric hospitals of Tehran anti HAV antibodies determined 22.3%.[9] Later, a number of articles reported different prevalence in variety of regions. In northern of Iran, Babol among HBV carriers, HAV Ab detected high increasing with age (59.4-97.5%),[10] also in same region anti HAV Ab prevalence reported in Sari 38.9%[11] and in Savadkoh 19.20%[12] but it increases 98.6% in Golestan province.[13] But in Isfahan province, the HAV prevalence was only 8.33% among 816 subjects over 6 years old, much lower prevalence than reported others.[14] Later in 2006 in a multicenter study, the researchers found the seroprevalence of HAV in Tehran, Golestan and Hormozgan provinces was 85%, 99%, and 96%.[15] Sofian et al. in 2010 detected 61.6% of total anti-HAV in capital city of Tehran[16] but recently published article reported 90% respectively.[17] In a study from Qazvin among blood donors in range of 17-60 years old, Ramezani reported 94.9% seropositivity.[18] in Sothern of Iran, Fars province 88.2%,[19] and among HCV infected people in Isfahan province 94.9% has been demonstrated.[20]Previous studies have shown that improvement of sanitation in some countries in the high-endemic area reduced the rate of HAV infection in children, although this seems to be desirable, reports exist on higher risk of outbreaks among the adult population who have not been exposed to HAV in their life before and are, therefore not immune.[4] Recently, Campagna et al. explained a significant declining trend of HAV epidemiology in an area of High endemicity of Italy. They declared the age specific seroprevalence has been found in people under 30 years; 61% in 1988, 33% in 1995 and 8.9% in 2005-2008.[21] In future, similar studies in Iran can help in designing vaccination guidelines customized according to HAV prevalence in various parts of the country and different populations.Today, an effective strategy to protect non-immune populations against HAV infection is necessary. Active immune prophylaxis by vaccination is the most important strategy for preventing disease at the national level.[22] This vaccine can induce lifelong immunity and is used in many developed countries, but this vaccine is not yet readily available in some developing countries. Also, it can control outbreaks in overcrowded, susceptible populations.[23] For example, vaccination has been indicated for travelers from low endemic areas to regions with higher prevalence of HAV.[24] In Iranian vaccination program, preventive immunization against HAV is not mandatory yet. In developing countries such as Iran following improvements in food and water hygiene, children's immunity has reduced, therefore hepatitis A vaccination should be considered and an immune survey should be done every few years to help health managers decide when to provide universal vaccination against the HAV.[23] In conclusion, the seroprevalence of HAV still appears to be too elevated for recommending routine vaccination in the general population. However, the trend towards a lower prevalence in younger age groups points towards the possible benefit of vaccination in this subgroup." @default.
• W1518669466 created "2016-06-24" @default.
• W1518669466 creator A5008370719 @default.
• W1518669466 creator A5015544777 @default.
• W1518669466 date "2013-08-01" @default.
• W1518669466 modified "2023-09-27" @default.
• W1518669466 title "Prevention of hepatitis a virus infection, need to vaccinate or not?" @default.
• W1518669466 cites W1431423267 @default.
• W1518669466 cites W1531443874 @default.
• W1518669466 cites W1570534137 @default.
• W1518669466 cites W1586307543 @default.
• W1518669466 cites W1783407889 @default.
• W1518669466 cites W1994364091 @default.
• W1518669466 cites W1999341638 @default.
• W1518669466 cites W2010242458 @default.
• W1518669466 cites W2011429977 @default.
• W1518669466 cites W2023050471 @default.
• W1518669466 cites W2049554510 @default.
• W1518669466 cites W2104691497 @default.
• W1518669466 cites W2111799124 @default.
• W1518669466 cites W2119295212 @default.
• W1518669466 cites W2129425349 @default.
• W1518669466 cites W2138249800 @default.
• W1518669466 cites W2151357530 @default.
• W1518669466 cites W2161429866 @default.
• W1518669466 cites W2265815154 @default.
• W1518669466 cites W294485059 @default.
• W1518669466 cites W3149034383 @default.
• W1518669466 cites W2241645062 @default.
• W1518669466 cites W2991839719 @default.
• W1518669466 cites W3023210024 @default.
• W1518669466 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3775161" @default.
• W1518669466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24049610" @default.
• W1518669466 hasPublicationYear "2013" @default.
• W1518669466 type Work @default.
• W1518669466 sameAs 1518669466 @default.
• W1518669466 citedByCount "2" @default.
• W1518669466 countsByYear W15186694662015 @default.
• W1518669466 countsByYear W15186694662016 @default.
• W1518669466 crossrefType "journal-article" @default.
• W1518669466 hasAuthorship W1518669466A5008370719 @default.
• W1518669466 hasAuthorship W1518669466A5015544777 @default.
• W1518669466 hasConcept C126322002 @default.
• W1518669466 hasConcept C159047783 @default.
• W1518669466 hasConcept C159654299 @default.
• W1518669466 hasConcept C203014093 @default.
• W1518669466 hasConcept C2775876817 @default.
• W1518669466 hasConcept C2776029263 @default.
• W1518669466 hasConcept C2777072776 @default.
• W1518669466 hasConcept C2777910003 @default.
• W1518669466 hasConcept C2778494684 @default.
• W1518669466 hasConcept C2908647359 @default.
• W1518669466 hasConcept C2994395758 @default.
• W1518669466 hasConcept C45189115 @default.
• W1518669466 hasConcept C71924100 @default.
• W1518669466 hasConcept C99454951 @default.
• W1518669466 hasConceptScore W1518669466C126322002 @default.
• W1518669466 hasConceptScore W1518669466C159047783 @default.
• W1518669466 hasConceptScore W1518669466C159654299 @default.
• W1518669466 hasConceptScore W1518669466C203014093 @default.
• W1518669466 hasConceptScore W1518669466C2775876817 @default.
• W1518669466 hasConceptScore W1518669466C2776029263 @default.
• W1518669466 hasConceptScore W1518669466C2777072776 @default.
• W1518669466 hasConceptScore W1518669466C2777910003 @default.
• W1518669466 hasConceptScore W1518669466C2778494684 @default.
• W1518669466 hasConceptScore W1518669466C2908647359 @default.
• W1518669466 hasConceptScore W1518669466C2994395758 @default.
• W1518669466 hasConceptScore W1518669466C45189115 @default.
• W1518669466 hasConceptScore W1518669466C71924100 @default.
• W1518669466 hasConceptScore W1518669466C99454951 @default.
• W1518669466 hasLocation W15186694661 @default.
• W1518669466 hasLocation W15186694662 @default.
• W1518669466 hasOpenAccess W1518669466 @default.
• W1518669466 hasPrimaryLocation W15186694661 @default.
• W1518669466 hasRelatedWork W1996196200 @default.
• W1518669466 hasRelatedWork W2001761823 @default.
• W1518669466 hasRelatedWork W2014176234 @default.
• W1518669466 hasRelatedWork W2017480042 @default.
• W1518669466 hasRelatedWork W2045158324 @default.
• W1518669466 hasRelatedWork W2047104268 @default.
• W1518669466 hasRelatedWork W2056913467 @default.
• W1518669466 hasRelatedWork W2059736792 @default.
• W1518669466 hasRelatedWork W2104691497 @default.
• W1518669466 hasRelatedWork W2129283647 @default.
• W1518669466 hasRelatedWork W2159574694 @default.
• W1518669466 hasRelatedWork W2409153513 @default.
• W1518669466 hasRelatedWork W2409988373 @default.
• W1518669466 hasRelatedWork W2416441651 @default.
• W1518669466 hasRelatedWork W2470512468 @default.
• W1518669466 hasRelatedWork W2899681755 @default.
• W1518669466 hasRelatedWork W2904666701 @default.
• W1518669466 hasRelatedWork W3025993811 @default.
• W1518669466 hasRelatedWork W3084244407 @default.
• W1518669466 hasRelatedWork W2262377079 @default.
• W1518669466 isParatext "false" @default.
• W1518669466 isRetracted "false" @default.
• W1518669466 magId "1518669466" @default.
• W1518669466 workType "article" @default.